Ayoxxa Biosystems GmbH, a Cologne, Germany- and Singapore-based international biotechnology company, completed a € 9,0m Series B financing round.
Backers included existing investors High-Tech Gründerfonds, KFW, NRW.BANK, Wellington Partners Venture Capital and private investors) and new investors b-to-v Partners AG, Creathor Venture and HR Ventures. In addition, several private investors from the US and Europe, including Ayoxxa employees and two of Qiagen’s founders, joined this financial round.
The company intends to use the funds to scale-up the production of proprietary biochips as well as to achieve international commercial readiness.
Led by Dr. Andreas Schmidt, CEO, Prof. Dieter Trau, CSO, and Dr. Markus Zumbansen, Vice President Research and Development, Michael Rasche, Corporate Vice President Global Commercial Operations, Ayoxxa has developed a proprietary technology platform for multiplex protein analysis.